Lilly

Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is pushing further into the psychedelic drug market with a US$2.8 billion buyout of clinical-stage developer AtaiBeckley (NASDAQ:ATAI). The crown jewel of the…

JPMorgan lifted Eli Lilly to $1,400 and AbbVie drew a string of target hikes as a new Medicare GLP-1 program widens access. Investorideas.com (www.investorideas.com newswire) a trusted platform for investing…

Lilly says experimental obesity drug delivered weight loss across all stages of menopause

Shares of Novo Nordisk and rival Eli Lilly fell on Tuesday after a report said price cuts are coming for popular weight-loss drugs.

Notable healthcare headlines for the week: AstraZeneca, Eli Lilly, Bristol Myers in focus